Fezagepras NEW
| Price | $48 | $68 | $97 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-06-22 |
Product Details
| Product Name: Fezagepras | CAS No.: 1002101-19-0 |
| Purity: 99.38% | Supply Ability: 10g |
| Release date: 2025/06/22 |
Product Introduction
Bioactivity
| Name | Fezagepras |
| Description | Fezagepras (Setogepram) is an orally active GPR40 agonist and is an antagonist or inverse agonist of GPR84 with anti-inflammatory, anti-fibrotic, and anti-proliferative actions. |
| In vitro | TGF-β (10 ng/mL)-activated human hepatic stellate cells (HSCs) proliferation inhibited by Setogepram (PBI-4050; 500 μM; 24 hours). Setogepram (PBI-4050; 250 or 500 μM; 24hours) dose-dependently arrests HSCs at the G0/G1 phase without inducing apoptosis [2]. |
| In vivo | In type 2 diabetes eNOS-/-db/db mice, Setogepram (PBI-4050; 100 mg/kg/day; gavage from 8-20 weeks of age) markedly decreases hyperglycemia and markedly improve glucose tolerance [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice./Shipping at ambient temperature. |
| Solubility Information | DMSO : 60 mg/mL (290.87 mM), Sonication is recommended. |
| Keywords | PBI4050 | PBI 4050 | Inhibitor | inhibit | GPR84 | GPR40 | G protein coupled receptor 84 | Free Fatty Acid Receptor | FFAR | Fezagepras | Diabetes,Kidney,Renal,Pancreatic,Liver,Fibrosis,Nephrology |
| Inhibitors Related | Vincamine | Monomethyl fumarate | Questiomycin A | 3-Hydroxyoctanoic Acid | Azathioprine | CRTh2 antagonist 2 | Fezagepras sodium | Benzyl nicotinate | TUG-1375 | CAY10595 | Timapiprant | NF-56-EJ40 |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $36.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-05-26 | |
| $48.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-06-22 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY